F043 New Drugs, New Rashes: An Update on Cutaneous Drug Eruptions
DESCRIPTION
Adverse drug reactions are inevitable sequelae of contemporary medical management and mucocutaneous eruptions rank among the most common of these reactions. Newer medications with significant drug eruption rates, and serious or characteristic cutaneous effects include newer anticancer drugs and the biologics. Distinctive reaction patterns, such as toxic epidermal necrolysis-like eruptions, are also emerging. It is a challenge for the practicing dermatologist to stay abreast of these new drugs and new rashes. Additionally, knowledge and management of severe drug eruptions in constantly evolving. This session will provide a comprehensive update on these eruptions and their management.
LEARNING OBJECTIVES
Describe drug culprits and current management of severe cutaneous adverse reactions.
Recognize and manage drug-induced toxic epidermal necrosis-like eruptions.
Assess, evaluate and treat cutaneous toxicities of new anticancer drugs and biologic therapies.
SCHEDULE
3:30 PM
Cutaneous side effects of immune checkpoint inhibitors (ICIs)
Timothy Dang, MD, FAAD
3:50 PM
Cutaneous side effects of oncology drugs other than ICIs
Connie Shi, MD, FAAD
4:20 PM
Q and A
Connie Shi, MD, FAAD, Timothy Dang, MD, FAAD
4:30 PM
Cutaneous side effects of biologic therapies
Jeffrey Marcus Cohen, MD, FAAD
4:55 PM
Updates in Severe Cutaneous Adverse Reactions - SJS/TEN and DRESS
Benjamin Kaffenberger, MD, MS, FAAD
5:20 PM
Q and A
Jeffrey Marcus Cohen, MD, FAAD, Benjamin Kaffenberger, MD, MS, FAAD
DIRECTOR
Connie Shi, MD, FAAD
SPEAKERS
Jeffrey Marcus Cohen, MD, FAAD
Department of Dermatology, Yale School of Medicine
Timothy Dang, MD, FAAD
Department of Dermatology, UC San Diego
Benjamin Kaffenberger, MD, MS, FAAD
HANDOUTS
DISCLOSURES
Jeffrey Marcus Cohen, MD, FAAD
Advarra – Data Safety Monitoring Board(Fees); GlaxoSmithKline Immunology – Consultant (1099 relationship)(Honoraria); Logical Images, Inc – Consultant(Honoraria); Novartis – Consultant (1099 relationship)(Fees); Sanofi – Consultant (1099 relationship)(Honoraria); Takeda Pharmaceuticals USA Inc – Advisory Board(Honoraria);
Timothy Dang, MD, FAAD
No financial relationships exist with ineligible companies.
Benjamin Kaffenberger, MD, MS, FAAD
Almirall – Consultant (1099 relationship)(Honoraria); Boehringer Ingelheim – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding); Dermatology Foundation – Investigator(Grants/Research Funding); Eli Lilly and Company – Consultant (1099 relationship)(Honoraria); HCW Biologics – Investigator(Grants/Research Funding); InflaRx – Consultant (1099 relationship)(Honoraria), Investigator(Grants/Research Funding); Janssen Biotech – Investigator(Grants/Research Funding); Leo Pharma – Investigator(Grants/Research Funding); National Comprehensive Cancer Network – Speaker(Honoraria);
Connie Shi, MD, FAAD
No financial relationships exist with ineligible companies.